Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pp375-430-Annex 1.Qxd
ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay, -
Exposure to Female Hormone Drugs During Pregnancy
British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low. -
Supplementary Tables, Figures and Other Documents
Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9 -
Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but Not Estradici1
[CANCER RESEARCH 44, 3862-3869, September 1984] Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but not Estradici1 James D. Yager,2 Harold A. Campbell, Daniel S. Longnecker, B. D. Roebuck, and Mary C. Benoit Departments ölAnatomy [J. D. Y.¡,Pathology [D. S. L], Pharmacology and Toxicology [B. D. R.¡,and Medicine [M. C. B.], Dartmouth Medical School, Hanover, New Hampshire 03756, and McArdle Laboratory tor Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706 [H. A. C.] ABSTRACT In experimental studies in animals, results have been obtained which suggest that synthetic estrogen treatment following car The effect of dietary exposure to synthetic estrogens on cinogen exposure (initiation) can enhance hepatic neoplasia. hepatocarcinogenesis was evaluated. Diethylnitrosamine-initi- Taper (32) was the first investigator to demonstrate that 2 ated and 0.85% NaCI solution-treated noninitiated female synthetic steroids used in oral contraceptive preparations in Sprague-Dawley rats were transferred to semisynthetic diets Europe, estradiol 17-phenylpropionate and estradiol benzoate, containing mestranol (0, 0.1, or 0.5 ppm), ethinyl estradiol (0.5 enhanced hepatocarcinogenesis in castrated female rats previ ppm), estradiol (0.6 ppm), or mestranol plus 0-methasone (0.5 ously initiated with A/-nitrosomorpholine In the United States, 2 and 0.2 ppm, respectively). 7-Glutamyl transferase (GGT>posi- synthetic estrogens, mestranol (170-ethinyl estradiol 3-methyl tive transections and hematoxylin and eosin-detectable nodules ether) and EE, are widely used in oral contraceptive preparations. and carcinomas were scored at 9 and 12 months. Quantitative We reported that, in intact, DEN-initiatedfemale Sprague-Dawley stereological calculations were performed to determine GGT rats, mestranol alone and together with norethynodrel enhanced lesion number and size. -
A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies. -
Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol Plus Hexestrol*T
Studies on Squamous Metaplasia in Rat Bladder II . Effects of Estradiol and Estradiol plus Hexestrol*t A. ANGRIST, P. CAPURRO, AND B. MOUMGIS (Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York 61, N.Y.) SUMMARY The effects of estrogens were studied with and without foreign body (rough glass beads and paraffin pellets) on the metaplasia of the bladder of rats on stock main tenance diet and on a vitamin A-deficient diet. Estradiol increased the degree of metaplasia in the bladder of rats when combined with vitamin A deficiency and/or foreign body stimulation. Estradiol affected bladder epithelium already made squamous more effectively than it did the normal transitional uroepithelium. A high dose of hexestrol, when added to estradiol, showed no enhance ment of the degree of metaplasi.a by estradiol benzoate in the bladder of the rat. The combination of vitamin A deficiency, foreign body in situ, and estrogenadminis tration was an effective means of obtaining keratinizing squamous metaplasia in the urinary bladder for studies of its developmental and reversal changes. In a previous presentation (4) the relation of The animals were divided into the following different forms of foreign-body irritation and of groups (the number of rats surviving with tissue vitamin A deficiency to squamous metaplasia in for study and the total number in each group mi the bladders of rats was reported. It is also known tinily are given following each group): that estrogens will cause squamous metaplasia. I. Stock diet + estradiol (6 survivals/lI rats) The metaplasia following estrogen administration II. -
Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar -
Diethylstilbestrol Lignant Cervical and Vaginal Tumors (Polyps, Squamous-Cell Papilloma, and Myosarcoma) in Female Hamsters, and Benign and Malignant Tes CAS No
Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Diethylstilbestrol lignant cervical and vaginal tumors (polyps, squamouscell papilloma, and myosarcoma) in female hamsters, and benign and malignant tes CAS No. 56-53-1 ticular tumors (granuloma, adenoma, and leiomyosarcoma) in male hamsters. Prenatal exposure also caused uterine cancer (adenocarci Known to be a human carcinogen noma) in female mice and hamsters, benign ovarian tumors (cystad First listed in the First Annual Report on Carcinogens (1980) enoma and granulosacell tumors) in female mice, and benign lung Also known as DES, diethylstilboestrol, or stilboestrol tumors (papillary adenoma) in mice of both sexes. Prenatal expo sure did not cause tumors in monkeys observed for up to six years CH 3 after birth. Mice developed cervical and vaginal tumors after receiv H2C ing a single subcutaneous injection of diethylstilbestrol on the first C OH day of life, and male rats developed cancer of the reproductive tract HO C (squamouscell carcinoma) after receiving daily subcutaneous injec CH2 tions for the first month of life. Diethylstilbestrol also caused cancer in experimental animals ex H3C Carcinogenicity posed as adults. When administered orally, diethylstilbestrol caused cancer of the mammary gland (carcinoma and adenocarcinoma) in Diethylstilbestrol is known to be a human carcinogen based on suffi mice of both sexes and benign mammarygland tumors (fibroade cient evidence of carcinogenicity from studies in humans. noma) in rats of both sexes. In addition, cancer of the cervix and uterus (adenocarcinoma), vagina (squamouscell carcinoma), and Cancer Studies in Humans bone (osteosarcoma) occurred in mice, and benign and malignant The strongest evidence for carcinogenicity comes from epidemiolog pituitarygland and liver tumors (hepatocellular tumors and heman ical studies of women exposed to diethylstilbestrol in utero (“diethyl gioendothelioma) occurred in rats. -
Estrogen, Progesterone and Contraceptives
Estrogen, Progesterone and Contraceptives BY: DR MEHERUNISA CIMS ASSOCIATE PROFESSOR ESTROGEN Actions • Female reproductive system: 1. Growth and development • CNS: 1. Feedback inhibition of gonadotropin (LH/FSH) secretion. 2. stimulation of CTZ to cause nausea and vomiting. • BLOOD: 1. Increased predisposition to deep vein thrombosis and pulmonary embolism due to increased synthesis of factor VII, VIII, IX and X and decreased production of antithrombin III by the liver. 2. Favourable effect on lipid profile by decreasing LDL and increasing HDL. ESTROGEN • METABOLIC 1. Glucose intolerance 2. Sodium and water retention. 3. Maintain bone mass by decreasing the bone resorption. • Increased risk of gall bladder stones and cholestatic jaundice. • Can result in hepatic adenoma on prolonged use. • Vasodilation by increasing the production of NO. ESTROGEN PREPARATIONS • Natural steroidal estrogen ✓Estrone, Estradiol ( maximum), Estriol • Synthetic steroidal estrogen ✓Ethinyl estradil ✓Mestranol ✓Tibolone • Synthetic non steroidal estrogens ✓Diethylstilbesterol ✓Dienestrol Pharmacokinetics ✓Natural estrogens: orally inactive due to first pass metabolism ✓Synthetic estrogens: orally active ✓Estradiol is converted to estrone and estriol in liver/ peripheral tissue ✓Orally administered estrogen → absorbed from intestine→ enterohepatic circulation → high hepatic to peripheral ratio→ hepatic side effects Therapeutic uses • Oral contraceptive pills ( OCP) • Postmenopausal Hormone Replacement Therapy ( HRT) • No progesterone/estrogen production after -
Combined Hormonal Contraceptive Use Among Breastfeeding Women: an Updated Systematic Review☆,☆☆ ⁎ Naomi K
Contraception 94 (2016) 262–274 Review article Combined hormonal contraceptive use among breastfeeding women: an updated systematic review☆,☆☆ ⁎ Naomi K. Teppera, , Sharon J. Phillipsb, Nathalie Kappb,c, Mary E. Gaffieldb, Kathryn M. Curtisa aDivision of Reproductive Health, US Centers for Disease Control and Prevention, Atlanta, GA 30341 bDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland (prior affiliation for Dr. Phillips and Dr. Kapp) cCurrent affiliation: Independent reproductive health consultant, Paris, France Received 27 March 2015; revised 13 May 2015; accepted 13 May 2015 Abstract Background: Contraception is important for women who are postpartum, including those who are breastfeeding. Use of combined hormonal contraceptives (CHCs) may affect breastfeeding performance and infant health outcomes. Objective: The objective was to identify evidence examining clinical outcomes for breastfeeding and infant health among breastfeeding women using CHCs compared to nonusers. Search strategy: We searched the PubMed database for all articles published from database inception through September 30, 2014. Selection criteria: We included primary research studies that compared breastfeeding women using CHCs with breastfeeding women using nonhormonal or no contraception, or compared breastfeeding women initiating combined hormonal contraception at early versus later times postpartum. Breastfeeding outcomes of interest included duration, rate of exclusive breastfeeding and timing of supplementation. -
For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007). -
Possible Developmental Early Effects of Endocrine Disrupters on Child
Endocrine disrupters and child health Possible developmental early effects of endocrine disrupters on child health Possible developmental early effects of endocrine disrupters on child health WHO Library Cataloguing-in-Publication Data Possible developmental early effects of endocrine disrupters on child health. 1.Endocrine disruptors. 2.Disorders of sex development. 3.Sex differentiation. 4.Environmental exposure. 5.Child. I. World Health Organization. ISBN 978 92 4 150376 1 (NLM classification: WK 102) © World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licens- ing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are en- dorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.